Advertisement
Advertisement

AVTX

AVTX logo

Avalo Therapeutics, Inc. Common Stock

18.08
USD
Sponsored
-0.08
-0.44%
Jun 25, 12:41 UTC -4
Open

AVTX Earnings Reports

Positive Surprise Ratio

AVTX beat 16 of 36 last estimates.

44%

Next Report

Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/
-$0.59
Implied change from Q1 26 (Revenue/ EPS)
--
/
-39.80%
Implied change from Q2 25 (Revenue/ EPS)
--
/
-69.27%

Avalo Therapeutics, Inc. Common Stock earnings per share and revenue

On May 13, 2026, AVTX reported earnings of -0.98 USD per share (EPS) for Q1 26, beating the estimate of -1.04 USD, resulting in a 6.32% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.45% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 9 analysts forecast an EPS of -0.59 USD, with revenue projected to reach -- USD, implying an decrease of -39.80% EPS, and increase of 0.00% in Revenue from the last quarter.
FAQ
For Q1 2026, Avalo Therapeutics, Inc. Common Stock reported EPS of -$0.98, beating estimates by 6.32%, and revenue of $0.00, 0% as expectations.
The stock price moved down -0.45%, changed from $19.94 before the earnings release to $19.85 the day after.
The next earning report is scheduled for Aug 05, 2026.
Based on 9 analysts, Avalo Therapeutics, Inc. Common Stock is expected to report EPS of -$0.59 and revenue of -- for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement